Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.
Saved in:
| Title: | Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. |
|---|---|
| Authors: | Lassman AB; Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian Hospital, New York, New York, USA.; Herbert Irving Comprehensive Cancer Center, New York, New York, USA., Pugh SL; RTOG Foundation Statistics and Data Management Center, American College of Radiology, Philadelphia, Pennsylvania., Wang TJC; Department of Radiation Oncology (in Neurological Surgery), Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian Hospital, New York, New York, USA.; Herbert Irving Comprehensive Cancer Center, New York, New York, USA., Aldape K; Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Gan HK; Cancer Therapies and Biology Group, Centre of Research Excellence in Brain Tumours, Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Melbourne, Australia.; La Trobe University School of Cancer Medicine, Heidelberg, Victoria, Australia.; Department of Medicine, University of Melbourne, Heidelberg, Victoria, Australia., Preusser M; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria., Vogelbaum MA; Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Sulman EP; Department of Radiation Oncology, New York University, Grossman School of Medicine, New York, New York, USA.; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA., Won M; RTOG Foundation Statistics and Data Management Center, American College of Radiology, Philadelphia, Pennsylvania., Zhang P; RTOG Foundation Statistics and Data Management Center, American College of Radiology, Philadelphia, Pennsylvania., Moazami G; Department of Ophthalmology, Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian Hospital, New York, New York, USA., Macsai MS; NorthShore University HealthSystem, Department of Ophthalmology, University of Chicago Pritzker School of Medicine, Evanston, Illinois, USA., Gilbert MR; Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA., Bain EE; Abbvie, Inc., North Chicago, Illinois, USA., Blot V; Abbvie, Inc., North Chicago, Illinois, USA., Ansell PJ; Abbvie, Inc., North Chicago, Illinois, USA., Samanta S; Abbvie, Inc., North Chicago, Illinois, USA., Kundu MG; Abbvie, Inc., North Chicago, Illinois, USA., Armstrong TS; Neuro-Oncology Branch, National Cancer Institute, Bethesda, MD, USA., Wefel JS; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Seidel C; University Hospital Leipzig, Leipzig, Germany., de Vos FY; University Medical Center Utrecht, Cancer Center, Utrecht, The Netherlands., Hsu S; Department of Neurosurgery, University of Texas Health Sciences Center, McGovern School of Medicine, Houston, Texas, USA., Cardona AF; Foundation for Clinical and Applied Cancer Research-FICMAC/Clinical and Translational Oncology Group, Brain Tumor Section, Bogotá, Colombia., Lombardi G; Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy., Bentsion D; Sverdlovsk Regional Oncology Center, Ekaterinburg, Russia., Peterson RA; Metro Minnesota NCORP, Saint Paul, Minnesota, USA., Gedye C; Calvary Mater Newcastle, Waratah, New South Wales, Australia., Bourg V; Department of Neurology, Côte d'Azur University, Nice, France., Wick A; Heidelberg University Medical Center, Heidelberg, Germany., Curran WJ; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Mehta MP; Miami Cancer Institute, Baptist Hospital, Miami, Florida, USA. |
| Source: | Neuro-oncology [Neuro Oncol] 2023 Feb 14; Vol. 25 (2), pp. 339-350. |
| Publication Type: | Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1523-5866 |
|---|---|
| DOI: | 10.1093/neuonc/noac173 |
